Proteotype Diagnostics employs innovative technologies centered around the concept of Liquid Biopsy, which allows for the profiling of the host response as a leading indicator of disease development. By determining an individual's unique proteotype, the company aims to predict treatment responses prior to the administration of therapies, such as drugs or surgical interventions. This predictive capability is complemented by a monitoring system that tracks changes in the proteotype, providing a minimally invasive method to assess on-treatment responses, including the potential for acquired resistance to therapies. This approach not only enhances patient care but also has the potential to inform adjustments in treatment plans based on real-time data.

The company's platform utilizes bio-orthogonal chemistry to create modular protein cross sections (PCS), which yield quantitative digital readouts from various bio-fluids, including plasma, urine, and potentially saliva and cells. This technology offers robust signals that provide novel insights into biological processes and is adaptable for rapid development of diagnostics across a range of diseases, including cancer, autoimmune disorders, and neurodegenerative conditions. The ability to design new diagnostics quickly, using diagnostic samples paired with clinical data, positions Proteotype Diagnostics to address significant unmet medical needs and expand into new indications efficiently.

United Kingdom

We profile the fundamental building blocks of life, providing cross-sectional snapshots, like a CT scan for your blood.

We want to impact both primary and secondary care pathways. 

Our mission is to light the way in which cancer is diagnosed, treated and monitored. 

We aspire to deploy at population-level within the UK and globally.

Proteotype Diagnostics

Company Details